

Short Communication

Immunodetection of heparin-binding growth associated molecule (pleiotrophin) in striatal interneurons

Irene R.E. Taravini^{a,*}, Juan E. Ferrario^b, Jean Delbe^c, Laure Ginestet^b, Thomas Debeir^b, José Courty^c, M. Gustavo Murer^d, Oscar S. Gershanik^a, Rita Raisman-Vozari^b^aLaboratorio de Parkinson Experimental, Instituto de Investigaciones Farmacológicas, CONICET, Junín 956, 5 Piso, C1113AAD, Buenos Aires, Argentina^bINSERM U679 Neurology and Experimental Therapeutics, Hôpital de la Salpêtrière, and Université Pierre et Marie Curie Faculté de Médecine, 75013 Paris, France^cLaboratoire de Recherche sur la Croissance Cellulaire, la Réparation et la Régénération Tissulaires (CRRET), FRE CNRS 2412, Université Paris XII-Val de Marne, 94010 Créteil, France^dLaboratorio de Fisiología de Circuitos Neuronales, Departamento de Fisiología, Facultad de Medicina, Universidad de Buenos Aires, C1121ABG Buenos Aires, Argentina

Accepted 11 October 2005

Available online 2 December 2005

Abstract

Pleiotrophin (PTN), a developmentally-regulated trophic factor, is over-expressed in the striatum of parkinsonian rats. Because striatal PTN can provide trophic support to dopamine neurons, we identified the cellular types containing PTN in the striatum of adult rats. By means of fluorescent double-immunolabeling, we found PTN to co-localize with a neuronal nuclei marker but not with glial fibrillary acidic protein. The number, distribution, and morphology of the PTN-immunolabeled cells suggested that they were interneurons. Further double-immunolabeling studies ruled out PTN localization to calretinin- and parvalbumin-containing interneurons. Instead, ~40% of the PTN-immunolabeled neurons contained nitric oxide synthase or somatostatin and ~60% expressed the vesicular acetylcholine transporter, supporting that they were GABAergic nitric oxide synthase/somatostatin-containing and cholinergic interneurons. Further work is necessary to determine if PTN from striatal interneurons can provide trophic support to dopamine neurons.

© 2005 Elsevier B.V. All rights reserved.

Theme: Development and regeneration

Topic: Neurotrophic factors: expression and regulation

Keywords: Pleiotrophin; Striatal interneuron; Immunohistochemistry; Parkinson's disease

Pleiotrophin (PTN) is a neurite outgrowth-promoting factor [20] and a mitogen isolated from bovine uterus [15] which is highly expressed in the nervous system and non-neural tissues during embryonic and early postnatal development [23]. PTN expression in the adult central nervous system is very low, but it can be induced in an activity-dependent manner [24] and after ischemic insults [22].

Recent studies revealed that PTN mRNA is increased in the striatum after nigrostriatal lesions [9] and chronic levodopa therapy [8]. As PTN promotes differentiation [9,16] of dopamine neurons in vitro, and increases the differentiation of embryonic stem cells to dopamine neurons [10], PTN might play an important role in nigrostriatal system development and in the compensatory mechanisms that take place in Parkinson's disease [4,17,25]. Therefore, it is important to determine what cellular elements express PTN in the basal ganglia. We have previously shown that unidentified cellular elements express PTN mRNA in the striatum [8]. Here, we performed Western blots and

* Corresponding author. Fax: +54 11 4963 8593.

E-mail address: taravini@ffyb.uba.ar (I.R.E. Taravini).

double-immunofluorescence on tissue sections to characterize PTN protein localization in the rat striatum.

Experiments were carried out on tissue samples from female Wistar rats (220–250 g) in compliance with the European Directive No.: 86/609/EEC. To obtain protein extracts for Western blot, the rats were anesthetized with ketamine and xylazine (40 mg/kg and 2 mg/kg i.p., respectively) and decapitated. The brain was removed and placed on a cold surface where the cerebral cortex and striatum were dissected out. The tissues were then placed in Tris 50 mM pH 7.4/NaCl 2 M containing a cocktail of protease inhibitors (Aprotinin 1 µg/ml, Leupeptins 1 µg/ml, Pepstatin A 1 µg/ml, PMSF 1 mM, EDTA 1 mM) and homogenized. Total protein concentration of the samples was measured using the BCA Protein Assay Kit (Pierce Biotechnology, USA). Western blots were performed on crude protein extracts (50 µg of total protein; Fig. 1a) and on a fraction of these extracts enriched in heparin-binding molecules (Fig. 1b). To concentrate the heparin-binding molecules, 200 µg of total protein (in 1 ml of Tris 50 mM pH 7.4/NaCl 0.5 M) was incubated at 4 °C overnight with 80 µl of heparin-conjugated Sepharose beads (10%, Amersham Biosciences, France), washed 3 times with 500 µl of Tris 50 mM pH 7.4/NaCl 0.5 M, then with Tris 50 mM pH 7.4. This procedure provided a very strong evidence that the antiserum has no cross-reactivity with other closely-related heparin-binding growth factors. The eluted proteins were electrophoresed on a 15% polyacrylamide gel and electrotransferred to an Immobilon-P membrane [16]. The membrane was incubated with the anti-PTN antiserum (rabbit polyclonal antibody directed against the amino acids 94–168 mapping at the carboxyl terminus of recombinant human PTN (rhPTN), 1:100, Santa Cruz Biotechnology, USA), a horseradish peroxidase-conjugated anti-immunoglobulin, and developed with standard chemiluminescent procedures. In order to test antiserum specificity, we exposed 3 ml of it (dilution 1:100) for 2 days to an Immobilon-P membrane containing 320 µg of rhPTN. Then, we eluted the specific anti-PTN antibodies

which were used to demonstrate the presence of PTN in protein extracts (Fig. 1b).

The antiserum revealed, both in cortical and striatal samples, an 18 kDa molecular weight band that matched the molecular weight of rhPTN, and additional bands of about 36, 15, and 12 kDa, which were not observed in the lane loaded with rhPTN. Preadsorption of the anti-PTN antiserum abolished all staining, while incubation of the blotted membranes with purified anti-PTN antibodies revealed the presence of the 18 kDa band and to some extent the other bands only in the brain protein samples (Fig. 1b). These results suggest that the 36 kDa band is a PTN dimer and the low molecular weight bands represent truncated forms of PTN produced *in vivo* [2,6,14].

To obtain tissue for immunohistochemistry, 7 rats were anesthetized and transcardially perfused with 4% paraformaldehyde in 0.1 M phosphate-buffered saline (PBS, pH 7.4). The brain was postfixed for 2 h, cryoprotected in solutions with increasing sucrose concentration, and serially cut in 40-µm-thick coronal sections. The free-floating sections were incubated for 48 h at 4°C with the anti-PTN antiserum (1:100), rinsed in PBS, and incubated for 2 h at room temperature with a biotin-labeled anti-rabbit IgG antiserum (1:250; Vector Laboratories, USA). The primary antibody was visualized by means of an avidin–biotin peroxidase complex and 3,3'-diaminobenzidine [17]. Two control conditions were tested to determine the specificity of PTN labeling in brain sections. First, the primary antiserum was omitted from the experimental protocol leading to no tissue labeling (not shown). Second, the primary antiserum was exposed to membranes containing rhPTN (see above), then the antiserum, devoid of the anti-PTN antibodies, was used to label brain sections. Overall, PTN was present in 145 ± 29 cells (mean \pm S.D., $n = 7$) per section per hemisphere (coronal plane 0.24 mm anterior from bregma, [19]) which were distributed throughout the striatum and had different neuron-like morphologies (Figs. 2a, b, c, d). Preadsorption of anti-PTN antibodies almost abolished the staining (Fig. 2f). Consistent with previous findings [5,21,23,24], PTN-immunoreactive neurons were found in




Fig. 1. Pattern of labeling produced by the anti-PTN antiserum in Western blot. Lanes contained crude proteins (a), extracted from cerebral cortex (Cx), striatum (St), or recombinant human pleiotrophin (rPTN, 50 ng). The antiserum weakly labeled an 18 kDa band corresponding to the PTN molecular weight. A similar blot, performed on extracts enriched in heparin-binding molecules (b), revealed some additional bands (left lanes). The pattern of labeling was almost abolished when the membrane was developed with an antiserum that was neutralized by previous incubation with rPTN (central lanes), and was reproduced by incubation with purified anti-PTN antibodies (right lanes). The arrows indicate weakly labeled bands.

Download English Version:

<https://daneshyari.com/en/article/9415735>

Download Persian Version:

<https://daneshyari.com/article/9415735>

[Daneshyari.com](https://daneshyari.com)